98%
921
2 minutes
20
We assessed cost-effectiveness of insertable cardiac monitors (ICMs) in a US cryptogenic stroke population. We modelled lifetime costs and quality-adjusted life years for three monitoring strategies post cryptogenic stroke: ICM starting immediately, ICM starting after Holter monitoring (delayed ICM) and standard of care involving intermittent ECG and Holter monitoring. Patient characteristics and detection efficacy were based on the CRYSTAL-AF trial. AF detection altered the modelled anticoagulation therapy and subsequent stroke and bleed risks. Immediate ICM was found to be cost-effective versus standard of care and cost-saving versus delayed ICM. Results were robust to sensitivity analyses. ICMs are a cost-effective diagnostic tool for the prevention of recurrent stroke in a US cryptogenic stroke population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2217/cer-2020-0224 | DOI Listing |
Catheter Cardiovasc Interv
September 2025
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Patent foramen ovale (PFO) has been identified as a potential risk factor for cryptogenic stroke (CS). Although transesophageal echocardiography (TEE) is considered the gold standard for PFO detection, false-negative results remain a clinical concern, particularly in CS patients with high suspicion of PFO-related etiology.
Aims: To evaluate the clinical utility of transcatheter PFO exploration (TPFOE) in CS patients with negative TEE findings but high suspicion of PFO-related etiology.
Cardiovasc Revasc Med
September 2025
Division of Vascular Surgery, Cardiovascular Center, Tufts Medical Center, Boston, MA, USA; Tufts University School of Medicine, Boston, MA, USA. Electronic address:
Background: protamine sulfate is used to reduce bleeding risk after Carotid Artery Stenting (CAS), but its efficacy in personalized patient settings remains underexplored. This study aims to identify factors associated with greater benefits from protamine sulfate following CAS.
Methods: A retrospective review of Vascular Quality Initiative (VQI) data (2016-2022) identified patients undergoing CAS, divided into Transfemoral CAS (TF-CAS) and Transcarotid artery revascularization (TCAR) groups.
Eur J Public Health
September 2025
Research Group of Anesthesiology, Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland.
Endovascular therapy (EVT) is standard care for acute ischemic stroke due to large vessel occlusion, but its availability is limited in areas with long distances. It has also been demonstrated that there are differences in the utilization of thrombectomy related to socioeconomic factors. The aim of this study is to examine regional differences in the utilization of mechanical thrombectomy and outcome within one comprehensive stroke center district in terms of distance and income.
View Article and Find Full Text PDFArch Phys Med Rehabil
September 2025
Department of Rehabilitation Medicine, Wuxi Central Rehabilitation Hospital, The Affiliated Mental Health Center of Jiangnan University, Wuxi, Jiangsu, China. Electronic address:
Objective: To identify baseline factors linked to a positive response to intermittent theta-burst stimulation (iTBS) in individuals with stroke.
Design: Secondary analysis of a randomized controlled trial.
Setting: A single rehabilitation hospital.
Chem Biodivers
September 2025
School of Pharmaceutical Science, Yunnan Key Laboratory of Pharmacology for Natural Products/College of Modern Biomedical Industry, NHC Key Laboratory of Drug Addiction Medicine, Kunming Medical University, Kunming, P. R. China.
20(R)-ginsenoside Rg3 can reduce the effects of oxidative stress and cell death in cerebral ischemia‒reperfusion injury (CIRI). Neuroinflammation is crucial post-CIRI, but how 20(R)-Rg3 affects ischemia‒reperfusion-induced neuroinflammation is unclear. To study 20(R)-Rg3's effects on neuroinflammation and neuronal preservation in stroke models and explore toll-like receptor 4/myeloid differentiation factor-88/nuclear factor kappa B (TLR4/MyD88/NF-κB) pathway mechanisms.
View Article and Find Full Text PDF